Felix Vaura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Felix Vaura has a total of 381 co-authors. Here are the top co-authors by number of shared publications:
- Maija Hollmén
MediCity Research Laboratory and InFLAMES Flagship, University of Turku, Turku, Finland
12 shared publications - Akira Takeda
University of Turku
11 shared publications - Anna Minchom
Drug Development Unit, Royal Marsden/Institute of Cancer Research, Sutton, UK
11 shared publications Annika Pasanen
11 shared publications- Debbie G. J. Robbrecht
Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands
11 shared publications Jami Mandelin
11 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
Congenital Left-sided Lesions and Cardiovascular Outcomes: Genetic Insights From FinnGen
Background and aims: Congenital heart disease (CongHD) is associated with increased risk of later cardiovascular disease (CVD). We examined later-onset CVD risk among individuals with congenital left-sided lesions (LSL) and early-onset aortic valve disease (AVD) and investigated shared genetic susceptibility between left-sided lesions and adult cardiovascular phenotypes. Methods: We studied 500,000 individuals from FinnGen. Clinical analyses evaluated congenital LSL (ICD-10 Q23–Q25) and early-onset AVD (ICD-10 I35 diagnosed <50 years) in relation to risk for atrial fibrillation, hypertension, myocardial infarction and heart failure using Cox proportional hazards models. Genome-wide association analyses for these phenotypes were performed in FinnGen using REGENIE, with replication in the UK Biobank. Associations of lead variants with CVD outcomes in the general population were assessed using Cox models. Results: The study included 1,616 individuals with congenital LSL, 1,039 with early-onset AVD, and 496,171 controls in FinnGen. Both groups were associated with earlier cardiovascular morbidity across the studied CVD outcomes. The combined genetic analysis identified two genome-wide significant loci: rs35046143 in LINC01708 (OR 1.23, 95% CI 1.17–1.30), a previously reported cardiovascular locus, and rs9503273 in MYLK4 (OR 0.82, 95% CI 0.76–0.88). The rs35046143 association was replicated in UK Biobank. In the general population, rs35046143 was associated with atrial fibrillation (HR 1.03, 95% CI 1.02–1.05). Conclusion: Congenital LSL and early-onset AVD were associated with increased and earlier recorded cardiovascular morbidity. The association of the LINC01708 locus with both CongHD and adult cardiovascular phenotypes in the general population provides evidence compatible with shared genetic susceptibility.
- 13 November 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
Open AccessCongenital Left-sided Lesions and Cardiovascular Outcomes: Genetic Insights From FinnGen
Background and aims: Congenital heart disease (CongHD) is associated with increased risk of later cardiovascular disease (CVD). We examined later-onset CVD risk among individuals with congenital left-sided lesions (LSL) and early-onset aortic valve disease (AVD) and investigated shared genetic susceptibility between left-sided lesions and adult cardiovascular phenotypes. Methods: We studied 500,000 individuals from FinnGen. Clinical analyses evaluated congenital LSL (ICD-10 Q23–Q25) and early-onset AVD (ICD-10 I35 diagnosed <50 years) in relation to risk for atrial fibrillation, hypertension, myocardial infarction and heart failure using Cox proportional hazards models. Genome-wide association analyses for these phenotypes were performed in FinnGen using REGENIE, with replication in the UK Biobank. Associations of lead variants with CVD outcomes in the general population were assessed using Cox models. Results: The study included 1,616 individuals with congenital LSL, 1,039 with early-onset AVD, and 496,171 controls in FinnGen. Both groups were associated with earlier cardiovascular morbidity across the studied CVD outcomes. The combined genetic analysis identified two genome-wide significant loci: rs35046143 in LINC01708 (OR 1.23, 95% CI 1.17–1.30), a previously reported cardiovascular locus, and rs9503273 in MYLK4 (OR 0.82, 95% CI 0.76–0.88). The rs35046143 association was replicated in UK Biobank. In the general population, rs35046143 was associated with atrial fibrillation (HR 1.03, 95% CI 1.02–1.05). Conclusion: Congenital LSL and early-onset AVD were associated with increased and earlier recorded cardiovascular morbidity. The association of the LINC01708 locus with both CongHD and adult cardiovascular phenotypes in the general population provides evidence compatible with shared genetic susceptibility.
- 1 October 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (5) , e005666
Polygenic Prediction of Non-goal Response to Statin Therapy
BACKGROUND: Genetic differences may contribute to interindividual variability in LDL-C (low-density lipoprotein cholesterol) lowering with statin therapy. Polygenic risk scores may help identify individuals unlikely to achieve guideline-concordant LDL-C targets on statins, enabling earlier therapy intensification. METHODS: We developed a multiancestry polygenic risk score for statin non-goal response (PRS-NGR) and evaluated its association with failure to achieve an on-statin LDL-C level of ≤70 mg/dL and with percent LDL-C reduction. This longitudinal cohort study used genotyping and electronic health record-linked data from the All of Us Research Program (2018–2025), the UK Biobank (2014–2023), and the Biobank Japan (2003–2008). Participants were statin users with at least 1 prestatin and 1 on-statin LDL-C measurement. Associations were assessed overall and by genetic ancestry, with replication in the UK Biobank and Biobank Japan. RESULTS: The study included 46 564 participants from All of Us, 37 009 from the UK Biobank, and 3613 from Biobank Japan. In All of Us, higher PRS-NGR was associated with increased odds of non-goal response (odds ratio per SD, 1.43 [95% CI, 1.37–1.49]). Compared with the middle quintile, individuals in the top 1% had a higher risk, whereas those in the bottom 1% had a lower risk of non-goal response. Associations of PRS-NGR were consistent across African, European, and Latin American ancestry groups. Each SD increase in PRS-NGR corresponded to a 1.2-percentage-point smaller LDL-C reduction. Findings were replicated in the UK Biobank (odds ratio per SD, 2.39 [95% CI, 2.23–2.57]) and in Biobank Japan (odds ratio per SD, 1.31 [95% CI, 1.17–1.46]). Integration of PRS-NGR with guideline-based criteria identified individuals who derived a higher LDL-C% change and increased identification of statin-eligible individuals. CONCLUSIONS: We developed and validated a multiancestry polygenic risk score that estimates the risk of non-goal LDL-C response to statin therapy. Incorporation of polygenic risk into lipid-lowering treatment paradigms may improve risk stratification and support more tailored therapy intensification strategies.
- 1 October 2026
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 19 (5) , e005666
Polygenic Prediction of Non-goal Response to Statin Therapy
BACKGROUND: Genetic differences may contribute to interindividual variability in LDL-C (low-density lipoprotein cholesterol) lowering with statin therapy. Polygenic risk scores may help identify individuals unlikely to achieve guideline-concordant LDL-C targets on statins, enabling earlier therapy intensification. METHODS: We developed a multiancestry polygenic risk score for statin non-goal response (PRS-NGR) and evaluated its association with failure to achieve an on-statin LDL-C level of ≤70 mg/dL and with percent LDL-C reduction. This longitudinal cohort study used genotyping and electronic health record-linked data from the All of Us Research Program (2018–2025), the UK Biobank (2014–2023), and the Biobank Japan (2003–2008). Participants were statin users with at least 1 prestatin and 1 on-statin LDL-C measurement. Associations were assessed overall and by genetic ancestry, with replication in the UK Biobank and Biobank Japan. RESULTS: The study included 46 564 participants from All of Us, 37 009 from the UK Biobank, and 3613 from Biobank Japan. In All of Us, higher PRS-NGR was associated with increased odds of non-goal response (odds ratio per SD, 1.43 [95% CI, 1.37–1.49]). Compared with the middle quintile, individuals in the top 1% had a higher risk, whereas those in the bottom 1% had a lower risk of non-goal response. Associations of PRS-NGR were consistent across African, European, and Latin American ancestry groups. Each SD increase in PRS-NGR corresponded to a 1.2-percentage-point smaller LDL-C reduction. Findings were replicated in the UK Biobank (odds ratio per SD, 2.39 [95% CI, 2.23–2.57]) and in Biobank Japan (odds ratio per SD, 1.31 [95% CI, 1.17–1.46]). Integration of PRS-NGR with guideline-based criteria identified individuals who derived a higher LDL-C% change and increased identification of statin-eligible individuals. CONCLUSIONS: We developed and validated a multiancestry polygenic risk score that estimates the risk of non-goal LDL-C response to statin therapy. Incorporation of polygenic risk into lipid-lowering treatment paradigms may improve risk stratification and support more tailored therapy intensification strategies.
- Open Access
- 3 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Side effects in hypertension treatment: a pharmacogenomic analysis
Background and Aims: Up to half of patients switch or discontinue antihypertensive medications within the first year, but underlying mechanisms remain elusive. This study aimed to identify genetic predictors of antihypertensive medication use trajectories within the first year. Methods: Using longitudinal medication data from >400 000 genotyped antihypertensive medication users across three cohorts (FinnGen, the UK Biobank, and the Estonian Biobank), short-term antihypertensive medication use trajectories were classified as Continue, Switch, or Discontinue. Genome-wide association studies were performed across five medication classes. Results: In total, 14 genome-wide significant loci were identified for switching from angiotensin-converting enzyme inhibitors (ACEI) and dihydropyridine calcium channel blockers (dCCB) to other antihypertensive medications. For ACEI switching, evidence converged on the neurotensin-NTSR1 pathway, including a 320-fold Finnish-enriched protective missense variant in the neurotensin receptor gene NTSR1 (rs148569146 [G301R], odds ratio [OR] 0.49, P = 3.3 × 10−43) and a variant near RASSF9 (rs181941187, OR = 0.74, P = 1.2 × 10−49) tagging the neurotensin gene NTS. In drug–gene interaction analyses, NTSR1 G301R was associated with reduced ACEI-induced cough risk (OR 0.39, P = 8.1 × 10−4). The dCCB switching locus at CYP3A43 was in near-complete linkage (r2 = 0.99) with the functional CYP3A4*22 allele (rs35599367, OR 1.23, P = 6.1 × 10−10). A polygenic risk score (PRS) for ACEI switching predicted two-fold ACEI cough risk in the top 10% PRS compared with the middle 20% in an independent sample of the Estonian Biobank. Conclusions: These findings extend the bradykinin hypothesis of ACEI-induced cough by implicating neurotensin-NTSR1 signalling, pinpoint CYP3A4*22 as a novel functional predictor of dCCB switching with potential for genotype-guided prescribing, and validate medication use trajectories as a framework for pharmacogenetic discovery.
- 3 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Open AccessSide effects in hypertension treatment: a pharmacogenomic analysis
Background and Aims: Up to half of patients switch or discontinue antihypertensive medications within the first year, but underlying mechanisms remain elusive. This study aimed to identify genetic predictors of antihypertensive medication use trajectories within the first year. Methods: Using longitudinal medication data from >400 000 genotyped antihypertensive medication users across three cohorts (FinnGen, the UK Biobank, and the Estonian Biobank), short-term antihypertensive medication use trajectories were classified as Continue, Switch, or Discontinue. Genome-wide association studies were performed across five medication classes. Results: In total, 14 genome-wide significant loci were identified for switching from angiotensin-converting enzyme inhibitors (ACEI) and dihydropyridine calcium channel blockers (dCCB) to other antihypertensive medications. For ACEI switching, evidence converged on the neurotensin-NTSR1 pathway, including a 320-fold Finnish-enriched protective missense variant in the neurotensin receptor gene NTSR1 (rs148569146 [G301R], odds ratio [OR] 0.49, P = 3.3 × 10−43) and a variant near RASSF9 (rs181941187, OR = 0.74, P = 1.2 × 10−49) tagging the neurotensin gene NTS. In drug–gene interaction analyses, NTSR1 G301R was associated with reduced ACEI-induced cough risk (OR 0.39, P = 8.1 × 10−4). The dCCB switching locus at CYP3A43 was in near-complete linkage (r2 = 0.99) with the functional CYP3A4*22 allele (rs35599367, OR 1.23, P = 6.1 × 10−10). A polygenic risk score (PRS) for ACEI switching predicted two-fold ACEI cough risk in the top 10% PRS compared with the middle 20% in an independent sample of the Estonian Biobank. Conclusions: These findings extend the bradykinin hypothesis of ACEI-induced cough by implicating neurotensin-NTSR1 signalling, pinpoint CYP3A4*22 as a novel functional predictor of dCCB switching with potential for genotype-guided prescribing, and validate medication use trajectories as a framework for pharmacogenetic discovery.
- 1 February 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (2)
GWAS and Replication Analysis of Apparent Treatment-Resistant Hypertension
BACKGROUND: Resistant hypertension (RH), in which blood pressure remains elevated on ≥3 medications or controlled on ≥4 medications, increases the risk of adverse cardiovascular events nearly 50% more than primary hypertension. We sought to identify genetic drivers of RH in a reliable and generalizable manner. METHODS: We utilized FinnGen (discovery) and UKBB (UK Biobank, replication) data sets to identify potential genetic drivers of RH. Using standard RH definitions, we developed cohorts in each data set and performed genome-wide (genome-wide association studies) and transcriptome-wide association studies, as well as Mendelian randomization analysis to evaluate potential causal associations. RESULTS: We replicated 5 genetic loci in CASZ1, WNT2B, KCNK3, LSP1 , and near the EVX1/EVX1AS locus for RH. Of these, CASZ1 and WNT2B are strongly associated with aldosterone homeostasis, while KCNK3 and LSP1 are associated with pathways mediating vasodilation. EVX1/EVX1AS are involved in mesendodermal lineage differentiation during gastrulation. Gene- and pathway-based analyses identified associations with vascular and cardiac developmental pathways in addition to aldosterone synthesis and secretion pathways. Transcriptome-wide association study analyses identified 37 genes, of which the genetically regulated expression is associated with RH, with particularly strong tissue-specific associations with KCNK3 . Finally, Mendelian randomization identified possible causal association for 4 vascular risk factors (CRP [C-reactive protein]), triglycerides, waist circumference, and body mass index) with RH, with strong associations with identified lead variants. CONCLUSIONS: We identified distinct genetic variants associated with RH, including those implicating the role of hyperaldosteronism, highlighting distinct pathways and targets for more effectively treating RH.
- 1 February 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (2)
GWAS and Replication Analysis of Apparent Treatment-Resistant Hypertension
BACKGROUND: Resistant hypertension (RH), in which blood pressure remains elevated on ≥3 medications or controlled on ≥4 medications, increases the risk of adverse cardiovascular events nearly 50% more than primary hypertension. We sought to identify genetic drivers of RH in a reliable and generalizable manner. METHODS: We utilized FinnGen (discovery) and UKBB (UK Biobank, replication) data sets to identify potential genetic drivers of RH. Using standard RH definitions, we developed cohorts in each data set and performed genome-wide (genome-wide association studies) and transcriptome-wide association studies, as well as Mendelian randomization analysis to evaluate potential causal associations. RESULTS: We replicated 5 genetic loci in CASZ1, WNT2B, KCNK3, LSP1 , and near the EVX1/EVX1AS locus for RH. Of these, CASZ1 and WNT2B are strongly associated with aldosterone homeostasis, while KCNK3 and LSP1 are associated with pathways mediating vasodilation. EVX1/EVX1AS are involved in mesendodermal lineage differentiation during gastrulation. Gene- and pathway-based analyses identified associations with vascular and cardiac developmental pathways in addition to aldosterone synthesis and secretion pathways. Transcriptome-wide association study analyses identified 37 genes, of which the genetically regulated expression is associated with RH, with particularly strong tissue-specific associations with KCNK3 . Finally, Mendelian randomization identified possible causal association for 4 vascular risk factors (CRP [C-reactive protein]), triglycerides, waist circumference, and body mass index) with RH, with strong associations with identified lead variants. CONCLUSIONS: We identified distinct genetic variants associated with RH, including those implicating the role of hyperaldosteronism, highlighting distinct pathways and targets for more effectively treating RH.
- Open Access
- 1 February 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (2) , e25358
Value of Multiomics Over Clinical Risk Factors in Hypertension Prediction
BACKGROUND: Several omics methods have been successfully used in hypertension prediction. However, the predictive ability of various multiomics data has not been compared in the same study sample, and it is unknown whether they provide additional predictive value over a good clinical risk factor score. METHODS: Clinical data augmented with modern multiomics methods (systolic blood pressure polygenic risk score, nuclear magnetic resonance metabolite profiling, and gut microbiota) were assessed in 2573 nonhypertensive participants of the FINRISK 2002 cohort. All combinations of these different methods were incorporated into cross-validated machine learning models to predict incident hypertension. Model performance of all combinations of these was assessed using the area under the curve (AUC). Information on incident hypertension was collected using nationwide healthcare register data. RESULTS: Over a mean follow-up of 18.0 years, 393 participants developed hypertension. Models that included the clinical and genetic data resulted in the highest mean AUC (0.735) compared with clinical risk factors alone (AUC=0.725). In the whole study sample, an SD increase in the polygenic risk score was associated with 29% (95% CI, 14%–46%) greater odds of incident hypertension after adjusting for clinical risk factors. Combining metabolome (AUC=0.709) or microbiota (AUC=0.720) data with clinical risk factors did not result in improved risk prediction. CONCLUSIONS: The best prediction combination model for incident hypertension was the clinical model augmented with a polygenic risk score. These data suggest that polygenic risk scores provide limited incremental value over clinical risk factors when assessing risk of incident hypertension.
- 1 February 2026
- Published by Wolters Kluwer Health in Hypertension
- Vol. 83 (2) , e25358
Open AccessValue of Multiomics Over Clinical Risk Factors in Hypertension Prediction
BACKGROUND: Several omics methods have been successfully used in hypertension prediction. However, the predictive ability of various multiomics data has not been compared in the same study sample, and it is unknown whether they provide additional predictive value over a good clinical risk factor score. METHODS: Clinical data augmented with modern multiomics methods (systolic blood pressure polygenic risk score, nuclear magnetic resonance metabolite profiling, and gut microbiota) were assessed in 2573 nonhypertensive participants of the FINRISK 2002 cohort. All combinations of these different methods were incorporated into cross-validated machine learning models to predict incident hypertension. Model performance of all combinations of these was assessed using the area under the curve (AUC). Information on incident hypertension was collected using nationwide healthcare register data. RESULTS: Over a mean follow-up of 18.0 years, 393 participants developed hypertension. Models that included the clinical and genetic data resulted in the highest mean AUC (0.735) compared with clinical risk factors alone (AUC=0.725). In the whole study sample, an SD increase in the polygenic risk score was associated with 29% (95% CI, 14%–46%) greater odds of incident hypertension after adjusting for clinical risk factors. Combining metabolome (AUC=0.709) or microbiota (AUC=0.720) data with clinical risk factors did not result in improved risk prediction. CONCLUSIONS: The best prediction combination model for incident hypertension was the clinical model augmented with a polygenic risk score. These data suggest that polygenic risk scores provide limited incremental value over clinical risk factors when assessing risk of incident hypertension.
- Open Access
Pharmacogenomic architecture of antihypertensive switching implicates neurotensin-NTSR1 signaling in ACE inhibitor-induced cough
Early failure of antihypertensive medication treatment affects one in four patients, but the underlying mechanisms are poorly understood. We aimed to identify genetic determinants of antihypertensive treatment failure within the first year. Using longitudinal medication data from >400,000 genotyped antihypertensive medication users across 3 cohorts (FinnGen, the UK Biobank, and the Estonian Biobank), we classified short-term antihypertensive use trajectories as Continue, Switch, or Discontinue. We performed genome-wide association studies of switching across five major medication classes, followed by replication and downstream analyses linking genetic loci to medication-specific adverse events and clinical outcomes. We identified 14 genome-wide significant loci for switching from angiotensin-converting enzyme inhibitors (ACEI) and dihydropyridine calcium channel blockers (dCCB) to other antihypertensive medications. For ACEI switching, multiple independent signals converged on the neurotensin-NTSR1 pathway, including a 320-fold Finnish-enriched protective missense variant in the neurotensin receptor gene NTSR1 (rs148569146 [G301R], allele frequency [AF] 1.4%, odds ratio [OR] 0.49, P=3.3×10 −43 ) and a variant near RASSF9 (rs181941187, AF=9.0%, OR=0.74, P=1.2×10 −49 ) tagging the neurotensin gene NTS . In drug-gene interaction analyses, NTSR1 G301R was associated with reduced ACEI-induced cough risk (OR=0.39, P=8.1×10 −4 ). The dCCB switching locus at CYP3A43 was in near-complete linkage (r 2 =0.99) with the functional CYP3A4*22 allele (rs35599367, AF=3.4%, OR=1.23, P=6.1×10 −10 ). Our findings extend the bradykinin hypothesis of ACEI-induced cough by implicating neurotensin-NTSR1 signaling. We additionally characterize CYP3A4*22 as a mechanistically supported predictor of dCCB intolerance. Longitudinal medication trajectories offer a rich framework for pharmacogenetic discovery with potential for future genotype-informed antihypertensive medication selection. Graphical
Open AccessPharmacogenomic architecture of antihypertensive switching implicates neurotensin-NTSR1 signaling in ACE inhibitor-induced cough
Early failure of antihypertensive medication treatment affects one in four patients, but the underlying mechanisms are poorly understood. We aimed to identify genetic determinants of antihypertensive treatment failure within the first year. Using longitudinal medication data from >400,000 genotyped antihypertensive medication users across 3 cohorts (FinnGen, the UK Biobank, and the Estonian Biobank), we classified short-term antihypertensive use trajectories as Continue, Switch, or Discontinue. We performed genome-wide association studies of switching across five major medication classes, followed by replication and downstream analyses linking genetic loci to medication-specific adverse events and clinical outcomes. We identified 14 genome-wide significant loci for switching from angiotensin-converting enzyme inhibitors (ACEI) and dihydropyridine calcium channel blockers (dCCB) to other antihypertensive medications. For ACEI switching, multiple independent signals converged on the neurotensin-NTSR1 pathway, including a 320-fold Finnish-enriched protective missense variant in the neurotensin receptor gene NTSR1 (rs148569146 [G301R], allele frequency [AF] 1.4%, odds ratio [OR] 0.49, P=3.3×10 −43 ) and a variant near RASSF9 (rs181941187, AF=9.0%, OR=0.74, P=1.2×10 −49 ) tagging the neurotensin gene NTS . In drug-gene interaction analyses, NTSR1 G301R was associated with reduced ACEI-induced cough risk (OR=0.39, P=8.1×10 −4 ). The dCCB switching locus at CYP3A43 was in near-complete linkage (r 2 =0.99) with the functional CYP3A4*22 allele (rs35599367, AF=3.4%, OR=1.23, P=6.1×10 −10 ). Our findings extend the bradykinin hypothesis of ACEI-induced cough by implicating neurotensin-NTSR1 signaling. We additionally characterize CYP3A4*22 as a mechanistically supported predictor of dCCB intolerance. Longitudinal medication trajectories offer a rich framework for pharmacogenetic discovery with potential for future genotype-informed antihypertensive medication selection. Graphical
- Open Access
- 13 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data file 1 from Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial
Excel spreadsheets of mass spectrometry analysis
- 13 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data file 1 from Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial
Excel spreadsheets of mass spectrometry analysis
- Open Access
- 13 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data file 2 from Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial
Excel spreadsheet of differentially expressed genes in CD14+ monocytes
- 13 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data file 2 from Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial
Excel spreadsheet of differentially expressed genes in CD14+ monocytes
- Open Access
- 13 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data file 2 from Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial
Excel spreadsheet of differentially expressed genes in CD14+ monocytes
- 13 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data file 2 from Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial
Excel spreadsheet of differentially expressed genes in CD14+ monocytes
- Open Access
- 13 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data file 1 from Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial
Excel spreadsheets of mass spectrometry analysis
- 13 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data file 1 from Systemic Blockade of Clever-1 Elicits Lymphocyte Activation Alongside Checkpoint Molecule Downregulation in Patients with Solid Tumors: Results from a Phase I/II Clinical Trial
Excel spreadsheets of mass spectrometry analysis